352 related articles for article (PubMed ID: 8735174)
21. The relationship between terazosin dose and blood pressure response in hypertensive patients.
Achari R; Hosmane B; Bonacci E; O'Dea R
J Clin Pharmacol; 2000 Oct; 40(10):1166-72. PubMed ID: 11028256
[TBL] [Abstract][Full Text] [Related]
22. Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension.
Frick MH; Cox DA; Himanen P; Huttunen M; Pitkäjärvi T; Pörsti P; Pöyhönen L; Pyykönen ML; Reinikainen P; Salmela P
Am J Cardiol; 1987 May; 59(14):61G-67G. PubMed ID: 2884854
[TBL] [Abstract][Full Text] [Related]
23. Effects of oral and intravenous terazosin and head-up tilt on blood pressure responses in patients with hypertension.
Achari R; Hosmane B; Linnen P; Cavanaugh J; Baroldi P; Cohen A
J Clin Pharmacol; 1998 Jun; 38(6):545-53. PubMed ID: 9650545
[TBL] [Abstract][Full Text] [Related]
24. Alpha-1-adrenergic blockade and lipoprotein metabolism in essential hypertension.
Ferrier C; Beretta-Piccoli C; Weidmann P; Mordasini R
Clin Pharmacol Ther; 1986 Nov; 40(5):525-30. PubMed ID: 2876796
[TBL] [Abstract][Full Text] [Related]
25. Doxazosin in the treatment of patients with mild or moderate hypertension and mild or moderate renal insufficiency.
Bartels AC; de Vries PM; Oe LP; van Bronswÿk H; Donker AJ; Réveillaud RJ; Fillastre JP; Zech P
Am Heart J; 1988 Dec; 116(6 Pt 2):1772-7. PubMed ID: 2904749
[TBL] [Abstract][Full Text] [Related]
26. A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy.
Englert RG; Mauersberger H
Am Heart J; 1988 Dec; 116(6 Pt 2):1826-32. PubMed ID: 2904758
[TBL] [Abstract][Full Text] [Related]
27. Effect of prazosin GITS, atenolol, nifedipine SR, and enalapril on ADP-induced platelet aggregation.
Patki KC; Joglekar SJ; Kamat SK; Thatte UM; Yeolekar ME; Rege NN; Dahanukar SA; Nanivadekar AS
J Assoc Physicians India; 1998; Suppl 1():26-9. PubMed ID: 11229106
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension.
Deger G
Am J Med; 1986 May; 80(5B):62-7. PubMed ID: 2872809
[TBL] [Abstract][Full Text] [Related]
29. Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension.
Luther RR; Glassman HN; Estep CB; Schmitz PJ; Horton JK; Jordan DC
Am J Hypertens; 1988 Jul; 1(3 Pt 3):237S-240S. PubMed ID: 2901267
[TBL] [Abstract][Full Text] [Related]
30. Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin.
Agabiti-Rosei E; Muiesan ML; Rizzoni D; Zulli R; Calebich S; Beschi M; Castellano M; Muiesan G
J Hum Hypertens; 1992 Feb; 6(1):9-15. PubMed ID: 1349920
[TBL] [Abstract][Full Text] [Related]
31. A comparison of the effects of doxazosin and terazosin on the spontaneous sympathetic drive to the bladder and related organs in anaesthetized cats.
Ramage AG; Wyllie MG
Eur J Pharmacol; 1995 Dec; 294(2-3):645-50. PubMed ID: 8750729
[TBL] [Abstract][Full Text] [Related]
32. Terazosin: an effective once-daily monotherapy for the treatment of hypertension.
Dauer AD
Am J Med; 1986 May; 80(5B):29-34. PubMed ID: 2872804
[TBL] [Abstract][Full Text] [Related]
33. A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with untreated essential hypertension.
Lytle T; Coles S; Waite MA
J Hum Hypertens; 1991 Feb; 5(1):35-8. PubMed ID: 1674964
[TBL] [Abstract][Full Text] [Related]
34. Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension.
Torvik D; Madsbu HP
Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):69S-75S. PubMed ID: 2939870
[TBL] [Abstract][Full Text] [Related]
35. Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
Pool JL
Am J Cardiol; 1987 May; 59(14):46G-50G. PubMed ID: 2884853
[TBL] [Abstract][Full Text] [Related]
36. [Pressure and metabolic effects of terazosin in essential hypertension].
Valle R; Semplicini A; Serena L; Gebbin A; Fontebasso A; Gerardi G; De Toni R; Pessina AC
Cardiologia; 1994 Jun; 39(6):421-4. PubMed ID: 7923256
[TBL] [Abstract][Full Text] [Related]
37. Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men.
Kirby RS
Br J Urol; 1998 Sep; 82(3):373-9. PubMed ID: 9772873
[TBL] [Abstract][Full Text] [Related]
38. Experience with terazosin administered in combination with other antihypertensive agents.
Chrysant SG
Am J Med; 1986 May; 80(5B):55-61. PubMed ID: 2872808
[TBL] [Abstract][Full Text] [Related]
39. A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus.
Castrignano R; D'Angelo A; Pati T; Al Awady M; Tronca R; Crepaldi G
Am Heart J; 1988 Dec; 116(6 Pt 2):1778-84. PubMed ID: 2904750
[TBL] [Abstract][Full Text] [Related]
40. A double-blind comparative study of doxazosin and nitrendipine in patients with mild-to-moderate essential hypertension.
Nechwatal W; Berger J; Blumrich W; Bouzo H; Brandl K; Braun S; Laukaitis A; Müller G; Ryba W; Schreiegg J
Am Heart J; 1988 Dec; 116(6 Pt 2):1806-14. PubMed ID: 2904755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
